936 results on '"Maloney, Jennifer"'
Search Results
2. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
3. Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
4. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
5. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
6. Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
7. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
8. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
9. Strengthening health systems for access to gene therapy in rare genetic disorders
10. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
11. A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic Duodenitis
12. Baseline Demographics And Disease Characteristics Of Pediatric Patients With Eosinophilic Esophagitis (EoE) From The Randomised, Placebo-Controlled, Phase 3 EoE KIDS Study
13. Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS Trial
14. Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy.
15. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study
16. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
17. S1876 An Adaptive Phase 2/3 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults and Adolescents With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
18. S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
19. S461 Dupilumab Efficacy in Eosinophilic Esophagitis Persists for Histologic, Symptomatic, and Endoscopic Outcomes Regardless of Concomitant High-Dose Proton Pump Inhibitor Use
20. EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
21. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: a subgroup analysis of the phase 3 LIBERTY EoE TREET study.
22. Late Breaking Abstract - Efficacy and Safety of Dupilumab for COPD with Type 2 Inflammation Indicated by Elevated Eosinophils
23. Dupilumab Treatment in Patients With Hand and Foot Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
24. That’s a WRAP! Effects of the Wellness Recovery Action Plan on Occupational Performance of Allied Health Graduate Students
25. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases
26. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
27. ISID0650 - Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (liberty-pn prime and prime2)
28. Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review
29. Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION
30. Long-Term Dupilumab Treatment Effect On Safety And Clinical Efficacy In Children With Type 2 Asthma: LIBERTY ASTHMA EXCURSION
31. 344 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
32. Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated
33. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites
34. Short ragweeds is highly cross-reactive with other ragweeds
35. Timothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet
36. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber
37. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
38. ASSESSMENT OF THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN CHILDREN WITH ASTHMA (LIBERTY ASTHMA EXCURSION STUDY)
39. Safety and tolerability of a short ragweed sublingual immunotherapy tablet
40. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial
41. 867a: CLINICAL AND HISTOLOGICAL IMPROVEMENTS WITH WEEKLY DUPILUMAB TREATMENT IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS AT WEEK 24: WEEKLY AND EVERY 2 WEEKS’ RESULTS FROM PART B OF THE 3-PART LIBERTY EOE TREET STUDY
42. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults
43. Sa1258 EFFECT OF DUPILUMAB ON WEIGHT IN PEDIATRIC PATIENTS AGED 1 TO
44. Sa1254 DUPILUMAB IMPROVES ESOPHAGEAL FEATURES OF EOSINOPHILIC ESOPHAGITIS (EOE) AS MEASURED BY ENDOSCOPIC REFERENCE SCORE IN CHILDREN WITH EOE: 52-WEEK RESULTS FROM THE PHASE 3 EOE KIDS TRIAL
45. Sa1275 IMPROVEMENTS IN HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS ARE MAINTAINED, OR CONTINUE TO IMPROVE, WITH LONG-TERM DUPILUMAB TREATMENT, REGARDLESS OF PRIOR ESOPHAGEAL DILATION
46. Sa1256 DUPILUMAB IMPROVES HISTOPATHOLOGIC ENDPOINTS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: 52-WEEK RESULTS FROM THE PHASE 3 EOE KIDS TRIAL
47. Sa1255 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN CHILDREN AGED 1 TO
48. Dupilumab Reduces Biomarkers of Type 2 Inflammation in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Parts A and C of a Three-Part, Phase 3 LIBERTY EoE TREET Study
49. Efficacy of Anti-Allergen Therapeutics in Preclinical Allergy Model Systems Correlate with Symptomatic Relief in a Clinical Setting
50. Indigena.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.